Publications by authors named "Anais Portalier"
Article Synopsis
- - Acalabrutinib, a more advanced treatment for chronic lymphocytic leukemia, has a better safety profile than older drugs but lacks clear guidelines on managing its side effects, prompting a study to establish best practices.
- - A team of medical professionals across France found that hospital pharmacists should evaluate drug interactions before starting patients on acalabrutinib and advised against using it with certain medications that can increase risks of toxicity or reduce effectiveness.
- - The study highlighted the need for monitoring blood pressure during treatment, outlined protocols for managing procedures, and suggested headache management strategies, demonstrating the importance of teamwork in improving patient care while using acalabrutinib.
Article Synopsis
- Ibrutinib, a first-generation BTK inhibitor, increases the risk of invasive fungal infections, while the second-generation BTK inhibitor, acalabrutinib, has unknown effects on neutrophil antifungal activity despite only a few reported cases of aspergillosis during its use.
- Three new cases of invasive aspergillosis were identified in patients with chronic lymphocytic leukemia shortly after starting acalabrutinib therapy, raising concern about its impact on immune response.
- After one month of acalabrutinib treatment, neutrophils exhibited a reduced ability to fight against Aspergillus fumigatus, highlighting the need for close monitoring of patients on this medication for potential fungal infections.
The Bruton tyrosine kinase inhibitor ibrutinib has become a leading therapy against chronic lymphoid leukemia. Recently, ibrutinib has been associated with the occurrence of invasive fungal infections, in particular invasive aspergillosis. The mechanisms underlying the increased susceptibility to fungal infections associated with exposure to ibrutinib are currently unknown.
View Article and Find Full Text PDF